LSE:AZNPharmaceuticals
AstraZeneca HPP Trial Data Tests Rare Disease Growth Expectations
AstraZeneca (LSE:AZN) reported positive results from its global Phase III programme for efzimfotase alfa in hypophosphatasia.
The late stage trials showed strong efficacy and safety in children, with clinically meaningful benefits in defined adolescent and adult subgroups.
The data further builds out AstraZeneca's rare disease pipeline beyond its existing oncology and biopharma focus.
AstraZeneca, trading at around £152.3, has seen its share price return 12.1% year to date and 54.8% over...